Rolaids labeling deferral
This article was originally published in The Tan Sheet
Executive Summary
FDA grants Pfizer's request for seven-month extension of May 16 "Drug Facts" labeling compliance deadline for convenience roll packages of regular, extra-strength Rolaids, according to April 15 letter. Deferral was granted so firm can have additional time to "acquire, install and validate" equipment necessary to produce a compliant roll package (1"The Tan Sheet" March 18, 2002, In Brief)...
You may also be interested in...
Rolaids labeling deferral
Pfizer asks FDA for seven-month extension of May 16 "Drug Facts" labeling compliance deadline for convenience roll packages of regular, extra strength Rolaids. Additional time is necessary "to ensure...we can acquire, install and validate the equipment that is necessary to produce, on a reliable, repetitive basis, a 'compliant' roll package," Feb. 27 submission states. Pfizer cites Lil' Drug Store Products' petition for an industry-wide labeling deferral for convenience-size packages; FDA responded to the petition in January, saying a notice delaying the compliance date for such packages would be published in an upcoming Federal Register notice (1"The Tan Sheet" Feb. 4, 2002, p. 5)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.